Integrated multi-omics analysis identifies DARS2, MRTO4, and MRPL37 as novel biomarkers and potential therapeutic targets for bladder cancer.

In the IMvigor210 cohort, predictive analysis revealed that DARS2 and MRTO4 were significantly overexpressed in the complete response (CR) and partial response (PR) groups, whereas MRPL37, despite showing elevated expression in these groups, did not reach statistical significance (Fig. 8 G).

also in 111,027 other papers